Stockscreener 앱 받기
1.12
0.00%
0.00
전일 마감가:
$1.12
열려 있는:
$1.13
하루 거래량:
909.07K
Relative Volume:
0.58
시가총액:
$91.38M
수익:
$65,300
순이익/손실:
$-84.95M
주가수익비율:
-0.5794
EPS:
-1.9332
순현금흐름:
$-88.92M
1주 성능:
-2.61%
1개월 성능:
-35.63%
6개월 성능:
-52.34%
1년 성능:
-40.74%
1일 변동 폭
$1.11
$1.13
1주일 범위
$1.11
$1.23
52주 변동 폭
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.12 | 93.83M | 65,300 | -84.95M | -88.92M | -1.9332 |
VRTX
Vertex Pharmaceuticals Inc
|
424.83 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
703.44 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
786.32 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.44 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.58 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INO Stock Price, Quote & Chart | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill
Inovio Pharmaceuticals (INO) price target decreased by 12.21% to 6.90 - MSN
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals proposes securities offering - MSN
Inovio prices $17.5 million public offering of shares and warrants - MSN
Inovio Pharmaceuticals Inc (HAM:GBM) Stock Price, Trades & News - GuruFocus
Inovio Pharmaceuticals, Inc. (INO) Presents at World Federation of Hemophilia World CongressSlideshow - Seeking Alpha
INO Forecast, Price Target & Analyst Ratings | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill
Inovio Pharmaceuticals Q1 2025 Earnings Preview - MSN
Here's why Inovio (INO) looks ripe for bottom fishing - MSN
Inovio Pharmaceuticals (INO) Profitability Outlook | Q4 2025: EPS Beats ForecastsCommunity Buy Signals - Cổng thông tin điện tử tỉnh Lào Cai
INO (Inovio Pharmaceuticals) notches massive Q4 2025 EPS beat, but steep year-over-year revenue drop drags on share price.Trending Buy Opportunities - Xã Thanh Hà
What's going on with Inovio Pharmaceuticals stock on Tuesday? - MSN
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - TradingView
INOVIO Pharmaceuticals advances DNA medicines for Hemophilia A and rare disease treatment - Traders Union
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Tuesday, still underperforms market - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Q4 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $6 - Moomoo
INOVIO to Present Hemophilia Research at Global Conference - MyChesCo
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Investor Alert: Deadline in Lawsuit on April 07, 2026 - openPR.com
INO Deadline Today: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Sahm
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.17%
자본화:
|
볼륨(24시간):